Pharma’s Plans to Rebuild Health Care Include Overhauling 340B

New reports from drugmaker Janssen (left) and PhRMA recommend taking 340B drug discounts away from hospitals and contract pharmacies and giving them to patients.

New reports from pharmacy giant Janssen and Pharmaceutical Research and Manufacturers of America (PhRMA) suggest that the pharma sector could be making the 340B program an even bigger target than it has been in recent years.

Janssen’s report is

Read More »

Could Concern About Hospital Price Transparency Boost Push for More Hospital 340B Transparency?

Bipartisan concern in Congress about hospitals' compliance with new price transparency rules might enhearten drugmakers and others who want to impose reporting requirements on 340B hospitals. | Shutterstock

The bipartisan leaders of the U.S. House Energy and Commerce (E&C) Committee and its Health Subcommittee wrote to U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week asking him to enforce “full compliance” with the Trump administration’s hospital

Read More »

Historic U.S. Rise in STDs Boosts 340B’s Importance, STD Program Directors Say

340B drug discount savings help STD clinics and grantees expand access to quality and affordable sexual health care, the National Coalition of STD Directors (NCSD) says. | Shutterstock

News this week that sexually transmitted disease (STD) reported cases in the U.S. reached all-time highs for the sixth straight year shows why STD clinic access to 340B drug discounts is vital, state and local STD program directors say.

New

Read More »

340B Report Publisher and CEO Slafsky: Providers Need Swift Action on Contract Pharmacy

With Xavier Becerra in place as HHS secretary, 340B providers are hopeful he will act fast and decisively against drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting. | Shutterstock

340B health care providers are hopeful that U.S. health secretary Xavier Becerra will sanction six drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting, 340B Report Publisher and CEO

Read More »

News Alert: United Therapeutics Unveils 340B Contract Pharmacy Claims Submission Requirement

Drug manufacturer United Therapeutics on Monday told covered entities what they must do to keep getting 340B pricing from the company on its drugs when dispensed by the entities’ retail pharmacy partners.

Drug manufacturer United Therapeutics on Monday launched phase two of its restrictions on 340B contract pharmacy, telling covered entities what they must do to keep getting 340B pricing from the company on its drugs when dispensed by the entities’ retail

Read More »

Gilead’s HIV Drug Reimbursement Cut Will be Devastating, 340B Covered Entities Say

340B HIV/AIDS clinics say drugmaker Gilead's forthcoming cut in pharmacy reimbursement for the company's medicines that uninsured individuals get for free could rock their finances to the core. | Shutterstock

Drug manufacturer Gilead late last week announced a huge cut, effective Jan. 1, 2022, in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient assistance program (PAP). 340B HIV/AIDS

Read More »

340B Could Come Up During Congressional Hearings Thursday

From left to right, HHS Secretary Xavier Becerra, CMS Administrator nominee Chiquita Brooks-LaSure, and HHS Deputy Secretary nominee Andrea Palm will all be on Capitol Hill on Thursday.

The U.S. Senate Finance Committee is scheduled to hold a hearing Thursday morning on President Biden’s nominations of Chiquita Brooks-LaSure to run the U.S. Centers for Medicare & Medicaid Services, and Andrea Palm to be U.S. Health and Human Services

Read More »

MACPAC Backs Medicaid Change That Could Lower Some 340B Prices

Raising the Medicaid rebate percentage and inflation penalty on accelerated-approval drugs, as the Medicaid and CHIP Payment and Access Commission (MACPAC) recommends, could lead to lower 340B ceiling prices on those drugs.

Congressional Medicaid policy advisers voted Friday to recommend raising the Medicaid rebate percentage and inflation penalty on drugs that are quickly and conditionally approved to treat serious conditions that fill an unmet need.

If Congress follows the Medicaid and CHIP

Read More »

Express Scripts Defends 340B Claims ID Requirement

Express Scripts told 340B covered entities in recent letters that it has granted "numerous" extensions of time for pharmacies to comply with its new 340B claims identification process.

Pharmacy benefits manager Express Scripts (ESI) told a hospital group and an HIV/AIDS clinic in recent days that it has “already granted numerous pharmacies extensions” to its controversial new 340B claims identification requirement that went into effect March 1.

ESI

Read More »

340B Entities Won’t Share in BMS’s $75 Million Medicaid Drug Pricing Settlement

A whistleblower alleged that Bristol-Myers Squibb misreported prices on more than 200 drug products, reducing Medicaid rebates it owed to states.

340B covered entities were not included in Bristol-Myers Squibb’s $75 million settlement last week of a whistleblower’s claims that BMS “falsely reported improperly reduced average manufacturer prices” (AMPs) on multiple drugs from October 2007 through March 2016.

Ronald Streck, former

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live